Skip to main content
. Author manuscript; available in PMC: 2019 May 6.
Published in final edited form as: ACS Nano. 2018 Oct 4;12(10):10272–10280. doi: 10.1021/acsnano.8b05373

Figure 6. In vivo OVA vaccination of LbL drug film from microneedle surface upon charge inversion of PDM.

Figure 6.

(A) Film architecture schematics of [PAsp(EDDPA)/OVA]40 LbL coated microneedle. (B) Vaccination dosing and ELISA schedule, each dose is 0.5 μg of OVA by either PDM-mediated microneedle, subcutaneous, or intramuscular administration. (C) Serum OVA-specific IgG1 antibody level measured in mouse serum (n = 10/group). Values are reported as mean ± s.e.m. ***p < 0.0001, as analyzed by one-way ANOVA.